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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an intractable cancer with a dismal prognosis. 
MicroRNA-29a (miR-29a) is commonly downregulated in PDAC, however, mechanisms for its 
loss and role still remain unclear. Here we show that in PDAC, repression of miR-29a is directly 
mediated by MYC via promoter activity. RNA-seq analysis, integrated with miRNA target 
prediction, identified global miR-29a downstream targets in PDAC. Target enrichment coupled 
with gene ontology and survival correlation analyses identified the top five miR-29a 
downregulated target genes (LOXL2, MYBL2, CLDN1, HGK and NRAS) that are known to 
promote tumorigenic mechanisms. Functional validation confirmed that upregulation of miR-29a 
is sufficient to ablate translational expression of these five genes in PDAC. We show that the most 
promising target among the identified genes, LOXL2, is repressed by miR-29a via 3’-UTR 
binding. Pancreatic tissues from a PDAC murine model and patient biopsies showed overall high 
LOXL2 expression with inverse correlations with miR-29a levels. Collectively, our data delineate 
an anti-tumorigenic, regulatory role of miR-29a, and a novel MYC-miR-29a-LOXL2 regulatory 
axis in PDAC pathogenesis, indicating the potential of the molecule in therapeutic opportunities.
Implications—This study unravels a novel functional role of miR-29a in PDAC pathogenesis, 
and identifies a MYC-miR-29a-LOXL2 axis in regulation of the disease progression, implicating 
miR-29a as a potential therapeutic target for PDAC.
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Introduction
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most deadly forms of human 
malignancies. Being the fourth most lethal cancer in the United States, PDAC accounts for 
7% of all estimated cancer-related deaths (1). With an overall 5-year survival rate of less 
than 5% worldwide (2), the trend for PDAC is projected to worsen over the next decade, 
rendering PDAC the second leading cause of cancer-related deaths by 2030 (3). Due to lack 
of efficient biomarkers, PDAC remains undetected till an advanced, metastatic stage when 
the cancer is aggressive and resistant to current forms of therapeutic modalities (4). 
Therapeutic failure for PDAC can be attributed to the unique heterogeneous, immune-
suppressive tumor microenvironment, which interferes with drug efficacy and cytotoxic T-
cell infiltration in the cells (4,5). Over 90% of PDAC cases exhibit driver oncogenic Kras 
mutations with initiation of precursor, pancreatic intraepithelial neoplasia (PanIN) lesions, 
which lead to aggressive metastatic PDAC (6). Although mutational spectrum of PDAC has 
been well characterized (6–8), the knowledge is yet to yield effective targeted therapies. 
Further, there was no success with targeting Kras (9,10) or finding potent Kras inhibitors 
(11). Thus, there is a crucial need for investigating the molecular mechanisms of PDAC to 
identify de novo targets for the disease aimed at developing effective therapeutic strategies to 
prolong life expectancies of PDAC patients.
MicroRNAs (miRNAs) play pivotal roles in regulating a broad array of biological processes 
related to cancer pathogenesis (12). Particularly, studies have shown tumor suppressor 
miRNAs to be repressed in a wide variety of cancer types, which in turn, de-repress proto-
oncogenic factors promoting cancer phenotypes (12). In our previous reports, we 
demonstrated the pathological role of microRNA-29a (miR-29a) in PDAC tumor-stromal 
biology (13,14). We found miR-29a to remain downregulated in pancreatic cancer cells 
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(PCCs) and associated fibroblasts (13,14). However the mechanisms of miR-29a 
downregulation and its downstream effectors in PDAC is still unclear. The current study 
delineates the upstream regulation of miR-29a in PDAC and characterizes global miR-29a 
targetome in the disease. Here we reveal for the first time, the association of miR-29a-
LOXL2 axis is regulation of PDAC pathogenesis.
Materials and Methods
Accession Number
The RNA-seq data reported in this study is available at the GEO database under the 
accession number GSE128663.
Experimental Mice
KrasLSL.G12D/+; p53LSL.R172H/+ (KP) mice were generated and crossed with Pdx1-Cre mice 
to obtain the KrasLSL.G12D/+; p53R172H/+; Pdx1-Cre (KPC) mice used in this study. All 
animal protocols were reviewed and approved by the Indiana University Animal Care and 
Use Committee. Regulatory guidelines set by Guide for the Care and Use of Laboratory 
Animals of the National Institute of Health were followed for all animal housing, use and 
euthanasia procedures.
Patient Tissue Procurement
This study was reviewed and approved by the Indiana University (IU) Institutional Review 
Board (IRB) (IU IRB # 1312935090R004). Patient tissues were obtained as described 
previously (13).
Cell Culture
Normal human pancreatic epithelial cell lines HPNE (CRL-023, ATCC) and HPDE 
(T0018001, AddexBio), and PCC lines Panc-1 (CRL-1469, ATCC) and MIA PaCa-2 
(CRL-1420, ATCC) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
(11965092, Life Technologies) supplemented with 10% FBS. AsPC-1 (CRL-1682, ATCC) 
and BxPC-3 (CRL-1687, ATCC) PCC lines were grown in RPMI 1640 medium (11875–
093, Gibco™) supplemented with 10% FBS. Cells were grown in a humidified 5% CO2 
incubator at 37°C. Cell lines were authenticated by morphologic inspection and mycoplasma 
testing. Experiments were performed with cells of passage of <10.
RNA Extraction
Total RNA was extracted from cultured cells or frozen pancreatic tissues using Trizol 
Reagent (Invitrogen™). The concentration and purity of the extracted RNAs were measured 
using a Nanodrop 2000 Spectrophotometer (Thermo Fisher Scientific) and stored at −80°C 
for future use.
Quantitative Real time PCR (qRT-PCR)
RNA was reverse transcribed to generate cDNA using High capacity cDNA Reverse 
Transcription kit (4368814, Thermo Fisher Scientific) with random primers or custom 
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primer pool for miRNA (Applied Biosystems). miRNA and LOXL2 expressions were 
measured using TaqMan Assays. Other gene expressions were measured using SYBR Green 
assays with primers shown in Supplementary Table S1. Primary (pri)-miR-29a/b1 
(Hs03302672_pri) and mature miR-29a (ID: 002112) were normalized to endogenous 
control ACTA (Hs00426835_g1) and U6 snRNA (ID: 001973) respectively. Mouse LOXL2 
(Mm00804740_m1) expression was normalized to ACTB (Mm00607939_s1). Samples were 
run using ABI 7500 Real-Time PCR machine. Relative expressions were analyzed using 
ΔΔCT method.
Immunofluorescence Imaging
Immunofluorescence Imaging for MYC was performed as described in Supplementary 
Materials and Methods. Images were obtained using a Leica DM5000B microscope. 
Quantification of percent MYC nuclear localization was performed using ImageJ software. 
Data was charted and presented as the average quantification of four replicates for each cell 
line.
Chromatin Immunoprecipitation (CHIP)
CHIP experiments were carried out as described previously (15,16) with a few modifications 
as shown in Supplementary Materials and Methods.
Transfection of cultured cell lines
Exponentially growing PCCs were transfected using Dharmafect®1 Reagent (T-2001–01, 
Dharmacon) and with control (CN-001000–01) or miR-29a mimic (C-300504–07), or the 
following siRNAs from Dharmacon: siCTRL (D-001810–10-05), siMYC (L-003282–
02-0005), siSMAD4 (L-003902–00-0005), siGLI3 (L-011043–00-0005), siMYBL2 
(L-010444–00-0005), siLOXL2 (L-008020–01-0005), siCLDN1 (L-017369–00-0005), 
siHGK (L-003971–00-0002), and siNRAS (L-003919–00-0005), from Qiagen: miRNA 
inhibitor control (339126) or LNA miR-29a inhibitor (339121), following manufacturer’s 
protocol. Total protein or RNA was isolated 48 hrs post-transfection for western blot or 
qPCR analyses.
RNA-seq and Bioinformatics
Panc-1 and MIA PaCa-2 cells were transfected with control or miR-29a (n=3/group) 
following the protocol described above. Total RNA was extracted 48 hrs post-transfection 
using RNeasy Plus Mini Kit (74134, Qiagen) and the purity was assessed using a Nanodrop 
2000. Purified RNA quality was determined by a Bioanalyzer, then used to prepare libraries, 
and sequenced (pair end read 150 cycles) using an Illumina HiSeq 2000. RNA-seq quality 
was examined using the FastQC tool. Library obtained from each replicate consisted of 26– 
36 million short sequence reads that were re-mapped back to the reference genome (hg38) 
using STAR v2.5 (17), which yielded overall average read map ratios of 93.6% and 90% for 
Panc-1 and MIA PaCa-2 cell lines. Uniquely mapped sequencing reads were assigned to 
genes based on Gencode 25 using featureCounts (v1.6.2) (18). After filtering out low 
expressed genes with read count per million (CPM) <0.5 in greater than two samples, gene 
expression profiles were normalized using trimmed mean of M values (TMM) method, and 
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differential expression analysis was performed using edgeR (v3.20.8) (19,20). The 
differentially expressed genes (DEGs) were determined by cutoff p-value<0.05 after false 
discovery rate (FDR) adjustment and amplitude of fold change (FC) of gene expression 
greater than 2 linear FC.
TargetScan (v7.1) (21) was adopted to predict conserved miR-29a target genes. 
Hypergeometric model was used to calculate the overlap between DEGs and miR-29a 
predicted targets. Functional enrichment analyses on the DEGs were performed using 
DAVID (v6.8) database (https://david.ncifcrf.gov/). The miR-29a target gene levels in 
human PDAC and normal pancreatic tissues were obtained from the human protein atlas 
(https://www.proteinatlas.org/).
Genetic alterations of the transcription factors with predicted binding sites in pri-miR-29a/ 
b1 promoter in TCGA PDAC datasets were analyzed using the online cBioportal cancer 
genomics tool (http://www.cbioportal.org/).
Western Blot
Protein lysates were prepared with RIPA Buffer (PI-89900, Thermo Fisher Scientific) and 
quantified using BCA Protein Assay Kit (23225, Pierce Biotechnology). Equal amounts of 
total protein were loaded for immunoblot analysis. Immunoblots were probed with 
antibodies against MYC (5605S, Cell Signaling Technology), SMAD4 (38454S, Cell 
Signaling Technology), GLI3 (sc-74478, Santa Cruz Biotechnology), MYBL2 (sc-390198, 
Santa Cruz Biotechnology), LOXL2 (ab96233, Abcam), CLDN1 (4933S, Cell Signaling 
Technology), HGK (3485, Cell Signaling Technology), NRAS (ab77392, Abcam), E-
cadherin (ab40772, Abcam), Vimentin (D21H3, Cell Signaling), LAMB1 (D4Q4Z, Cell 
Signaling) and GAPDH (MA5–15738, Thermo Fisher Scientific) overnight at 4°C followed 
by incubation for 1 hr at room temperature with corresponding HRP conjugated goat anti-
mouse (31430, Thermo Fisher Scientific) or goat anti-rabbit (31460, Thermo Fisher 
Scientific) secondary antibodies. Western Blots were then developed using ECL detection kit 
(34096, Thermo Fisher Scientific) and captured on an Amersham Imager 600 (GE 
Healthcare). Densitometry analysis was performed using Image J software to quantify each 
protein band, and were normalized against LAMB1 for nuclear fraction or GAPDH.
Migration Assays
Migration assays with control or transfected Panc-1 and MIA PaCa-2 were performed as 
described in Supplementary Materials and Methods.
Estimation of Extracellular LOXL2 Secretion
PCCs transfected with control or miR-29a mimic, and siCTRL or siLOXL2 were grown in 
complete DMEM post-transfection for 24 hrs. 3 × 105 cells were then cultured in serum-free 
DMEM for 48 hrs. The resulting conditioned media (CM) were collected, and concentrated 
using Amicon Ultra-0.5 Centrifugal Filter Unit (UFC501096, MilliporeSigma). To quantify 
the extracellular LOXL2, Enzyme-linked immune sorbent assay (ELISA) was performed 
with the concentrated CM according to manufacturer’s protocol (DY2639–05, R&D 
Systems).
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Sircol Soluble Collagen Assay (Biocolor, Carrickfergus, United Kingdom) and 
Hydroxyproline Assay were performed as described previously (22) and in the 
Supplementary Materials and Methods.
Dual Luciferase Reporter Assay
For miR-29a promoter activity, upstream promoter region of miR-29a/b1 containing MYC 
binding sites was cloned into Luc2 Luciferase Expression vector (E6651, Promega). PCCs 
were co-transfected with control or siMYC, and MYC binding site Luc2 Luciferase vector 
using DharmaFECT Duo Transfection Reagent (T-2010–02, Dharmacon). For LOXL2 
promoter activity, LOXL2 3’-UTR wild type (3’-UTR WT) and mutant (3’-UTR MUT) 
luciferase vectors consisting of miR-29a binding site were constructed respectively. The 
PCCs were co-transfected with control or miR-29a mimic, and 3’-UTR WT, or control or 
miR-29a mimic, and 3’-UTR MUT. 48 hrs post-transfection, luciferase activity was 
measured by Dual Glo® Luciferase Assay System (E2920, Promega) following 
manufacturer’s instructions. Firefly luciferase luminescence was normalized to Renilla 
luciferase activity for each transfected well.
Immunohistochemistry
Immunohistochemistry with human and mouse pancreatic tissue sections was performed as 
described in Supplementary Materials and Methods.
Statistical Analyses
GraphPad Prism (v5) and Microsoft Excel were used for statistical analyses. All data were 
expressed as mean ± standard error of the mean (SEM) of three independent experiments. 
Statistical comparison between two groups was performed using two-tailed Student’s t-test, 
while for multiple comparisons, one-way ANOVA with Bonferroni’s correction was used. 
Chi square tests were performed for correlation analyses between miR-29a and target genes 
in histopathological samples. p< 0.05 was considered as statistically significant and are 
indicated with asterisks (*p< 0.05, **p<0.01, ***p<0.001).
Results
Pri-miR-29a/b1 expression is lower in PDAC cell lines and inversely correlates with MYC
miR-29 family includes miR-29a, −29b, −29c, encoded by polycistronic hsa-miR-29a/b1 
and miR-29c/b2 clusters, located on chr 7q32.3 and 1q32.2 respectively. These clusters are 
initially transcribed as long pri-miR-29a/b1 and pri-miR-29b2/c (23) and then processed by 
endonucleases to yield mature miR-29a, −29b and −29c (12,23). Our previous report 
demonstrated a robust reduction in miR-29a expression in pancreata from a well-
characterized Kras-driven PDAC mouse model, KC (LSL-KrasG12D/+; Pdx-1-Cre), PCC 
lines and human PDAC patients (13). We further demonstrated that among all miR-29 
members, miR-29a is most abundantly expressed in human pancreas, pancreatic stellate cells 
(PSCs), as well as in normal human pancreatic epithelial cell line (HPNE) (13). Therefore, 
in the current study we primarily focused on primary (pri-) miR-29a/b1 cluster and mature 
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miR-29a for functional analyses. First, we measured pri-miR-29a/b1 expression levels in 
four PCC lines (Panc-1, MIA PaCa-2, BxPC-3 and AsPC-1) and two normal human 
pancreatic ductal epithelial cell lines (HPNE and HPDE). Consistent with our previous 
observation with mature miR-29a (14), pri-miR-29a/b1 expression was significantly lower in 
each of the four tested PCC lines as compared to HPNE and HPDE (Fig. 1A).
To understand the potential mechanism of transcriptional repression of miR-29a in 
pancreatic cancer, we screened several candidate transcription factors (TFs) with predicted 
binding sites at the miR-29a promoter and are associated with PDAC. This identified five 
major TFs, namely MYC, SMAD4, YY1, GLI3, and NF-ĸB. Examining the TCGA 
pancreatic adenocarcinoma datasets at the cBioPortal, we observed >10% genetic alterations 
for MYC and SMAD4, 4% for GLI3 and little alterations of NF-ĸB and YY1 in PDAC 
patients (Fig. 1B). Similar patterns of genetic alterations were observed in PCC data 
obtained from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) (Supplementary 
Fig S1–A). In both PDAC patients and PCC lines, MYC exhibited the highest copy number 
alteration (amplification), while SMAD4 mainly associated with deletion and mutational 
changes. Interestingly, the miR-29a expression in these TCGA patients and PCC lines 
inversely correlated with MYC (Fig. 1C, Supplementary Fig S1–B). Because NF-ĸB and 
YY1 showed the least genetic alterations in the TCGA patient and CCLE PDAC cell data, 
and that both the genes are the effectors of the same NF-ĸB signaling pathway as GLI3, we 
chose to carry out our mechanistic study with MYC, GLI3 and SMAD4 in PCCs, and 
excluded NF-ĸB and YY1 from our further analyses.
To determine the association of these three TFs on miR-29a in PDAC, we first performed 
RNAi mediated knockdown of the TFs in Panc-1 cells (Fig. 1D). Our results indicated a 
significant (>2 fold) increase in miR-29a expression (p< 0.05) only for MYC KD among the 
tested TFs (Fig. 1E). Further, we observed ~ 2.5 fold increase in the expression of pri-
miR-29a/b1 for MYC KD in the Panc-1 cells (Fig. 1F). These results suggested an inverse 
relationship between MYC and miR-29a and hereafter, we focused on further exploring the 
regulatory role of MYC on miR-29a in pancreatic cancer.
Inhibition of MYC with small molecule inhibitor enhances miR-29a expression in PCCs
To further validate the repressive regulation of miR-29a by MYC, we treated Panc-1 cells 
with different doses of a small molecule MYC inhibitor, 10058-F4 (24,25). 10058-F4 
resulted in increased expression of miR-29a in a dosage dependent manner, with a 
significant rise in miR-29a level at 100μM treatment (Fig. 1G). These findings reinforce the 
inverse regulatory relationship between MYC and miR-29a in PCCs.
PCCs and Normal Pancreatic Epithelial Cells show differential localization of MYC in the 
nucleus
To find the mechanism of interaction of MYC with miR-29a promoter, we first investigated 
whether MYC is differentially localized in low and high miR-29a expressing PCCs. 
Immunofluorescence analysis revealed that in normal pancreatic epithelial cell lines (HPNE 
and HPDE) expressing higher pri-miR-29a/b1, MYC was minimally localized in the 
nucleus, while the low pri-miR-29a/b1 expressing PCC lines exhibited strong MYC nuclear 
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localization (Fig. 2A&B). To validate our immunofluorescence observations, we performed 
western blot analysis for MYC in the nuclear and cytoplasmic fractions of HPNE cells and 
PCCs. The MYC expressions were normalized to nuclear protein LAMB1 and cytosolic 
protein GAPDH for the nuclear and cytosolic fractions respectively, however both the 
fractions were blotted with LAMB1 and GAPDH to assess the quality of the fractionations. 
Western blots revealed MYC expression patterns similar to immunofluorescence, 
corroborating the findings (Fig 2C). In PCC lines, MYC localization was higher in the 
nucleus and lower in the cytosol, while in HPNE cells, the localization of MYC in the 
nuclear and cytoplasmic fractions were lower and higher respectively. These findings 
confirm the negative correlation between MYC and pri-miR-29a/b1 expressions, and 
indicate that abundance of MYC in the nucleus is likely responsible for miR-29a repression, 
suggesting a potential interaction between MYC and miR-29a in PCCs.
MYC represses miR-29a by direct promoter binding in PCCs
To gain mechanistic insights into MYC-miR-29a interaction, we next examined if 
miR-29a/b1 is directly modulated by MYC in PCC lines through promoter activity. 
MiR-29a/b1 promoter has two conserved MYC binding sites. One of these sites, located at 
−261 from the transcription start site, contains a canonical E-box binding motif 5’ 
CACGTG, while the other site located at −1317 consists of a 5’CACATG binding motif (26) 
(Fig. 2D). To determine the functional significance of these sites, we generated luciferase 
reporter constructs consisting of a WT miR-29a/b1 promoter which includes the two 
conserved MYC binding sites. Relative promoter activity was determined by co-transfecting 
each cell line with promoter luciferase plasmid containing the WT MYC binding sites and 
siMYC or siCTRL plasmids. In both Panc-1 and MIA PaCa-2 cells, a significantly increased 
luciferase activity was observed for MYC knockdown, indicating a direct repressive role of 
MYC in miR-29a expression (Fig. 2E, Supplementary Fig. S1–C). To further validate MYC 
binding to miR-29a promoter, we performed CHIP assays using the two PCC lines. MYC 
CHIP was quantified by real-time PCR using two amplicons within the conserved region of 
miR-29a/b1 along with an amplicon in the CDKN1A promoter, which served as a positive 
control (15). Fold enrichment of the positive control in the MYC CHIP samples compared to 
CHIP samples with IgG antibody was set as the threshold (>12 folds) for MYC binding. In 
both PCC lines, MYC CHIP signals crossed the fold enrichment threshold, confirming the 
association of MYC with the repressed miR-29a/b1 promoter (Fig. 2F, Supplementary Fig. 
S1–D).Together, these results show that in PCCs, MYC directly binds to the promoter 
elements of miR-29a/b1 and represses miR-29a transcription.
RNA-seq identifies differentially expressed miR-29a targets
We next sought to identify global miR-29a effectors and delineate the downstream signaling 
mechanisms of miR-29a in PDAC. High-throughput RNA-seq with Panc-1 and MIA PaCa-2 
cells overexpressing miR-29a, along with those transfected with mimic control, generated a 
global miR-29a targetome. For analyzing the RNA-seq data and identifying the critical 
miR-29a targets, we employed a pipeline depicted in Figure 3A. RNA-seq dataset for Panc-1 
identified 6687 downregulated and 6311 upregulated genes while MIA PaCa-2 dataset 
revealed 7457 and 7633 down- and upregulated transcripts respectively (Fig. 3B, 
Supplementary Fig. S2–A). The differentially expressed genes (DEGs) for Panc-1 and MIA 
Dey et al. Page 8













PaCa-2 datasets exhibited high degree of correlation (Pearson’s Correlation Coefficient 
=0.69) (Fig. 3C). Thereafter, we applied stringent filters and considered only those DEGs 
which met the following criteria: logFC >± 1, FDR<0.05 and p<0.05. This identified 278 
and 369 genes in Panc-1, and 556 and 440 genes in MIA PaCa-2 datasets that were down- 
and up- regulated respectively (Fig. 3D, Supplementary Fig. S2–B). Next, we used 
TargetScan database (27) to identify predicted putative miR-29a targets among the DEGs in 
the two datasets. In both datasets, majority of the miR-29a targets were downregulated (Fig. 
3D, Supplementary Fig. S2–B). In Panc-1 dataset, of the downregulated genes, 108 genes 
were miR-29a targets, while 5 of the upregulated genes were miR-29a targets (Fig. 3D). 
Again, in MIA PaCa-2 dataset, 80 of all downregulated genes and 15 of all upregulated 
genes were predicted miR-29a targets (Fig. 3D). Comparison of the DEGs among the Panc-1 
and MIA PaCa-2 datasets revealed 43 downregulated, and 4 upregulated miR-29a target 
genes that overlapped in the two datasets (Fig. 3D, Supplementary Fig. S2–B, 
Supplementary Table S2). A subset of top 30 overlapping DEGs, with the highest average 
fold changes in Panc-1 and MIA Paca-2 cell lines, were subjected to qPCR, and all of the 30 
genes well-matched in magnitude and direction of expression, validating the RNA-seq data 
(Supplementary Table S3). Because majority of the miR-29a targets were downregulated in 
both the datasets, we focused on the resultant overlapping downregulated targets for further 
analyses. Consistent with our data, increasing evidence demonstrated the significance of 
miR-29a in variety of cancers, and majority of these studies have shown miR-29a to function 
as a tumor suppressor by downregulating oncogenes (12,14,28,29).
Target Enrichment, Gene Ontology (GO) and The Cancer Genome Atlas (TCGA) data 
analyses identify top miR-29a targets and their functional attributes in PDAC
To determine the biological function and signaling pathways associated with the miR-29a 
targets, pathway enrichment analysis was performed for the genes by inputting their Entrenz 
IDs into the functional annotation tool DAVID, and the genes were grouped one or more of 
the following four GO categories: ECM Related, Migration/Invasion, Cancer/Growth/
Proliferation, and Metabolism, based on relevant GO terms (30). Pathway analysis of the 20 
most differentially expressed overlapping upregulated genes identified 11 genes belonging to 
one of the four GO categories, but none of these genes were miR-29a targets. Of the top 20 
downregulated genes, 13 belonged to the GO categories, among which 10 genes were 
miR-29a targets (Supplementary Fig. S2–C). Overall, high enrichment scores and significant 
association of a vast majority of the miR-29a targets with individual GO terms was observed 
in each category (Fig. 3E and F). These findings are in agreement with the mechanisms of 
PDAC progression, which is characterized by desmoplasia, epithelial mesenchymal 
transition (EMT), metastasis, altered metabolism and drug resistance (4,31). To determine 
the most clinically relevant miR-29a targets and their prognostic impacts, we performed 
survival analysis for the 43 downregulated genes using publicly available TCGA patient 
data. This pipeline identified the seven miR-29a targets from the RNA-seq datasets- 
MYBL2/b-myb, LOXL2, CLDN1, MAP4K4/HGK, NRAS, FNDC5 and TUBD1 (Table 1) 
with highest fold changes in mRNA expressions in RNA-seq and logrank p <0.05 for 
Kaplan-Meier survival correlation analyses from TCGA data. Interestingly, Kaplan-Meier 
curve and log rank test analyses in pancreatic adenocarcinoma patients showed that lower 
expression of five of these genes, except FNDC5 and TUBD1, correlated with higher overall 
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survival of the patients (Fig. 4A). Consistently, the univariate Cox Proportional Hazard 
Regression model indicated a higher hazard risk in the patients for high expression of the 
five genes while a lower risk with higher expression of FNDC5 and TUBD1 (Table 1). Our 
previous reports and other studies in diverse tumor types document miR-29a to function as a 
tumor suppressor. Thus, hereafter we focused on the five targets of MYBL2, LOXL2, 
CLDN1, HGK and NRAS, where lower gene expression associated with better prognosis.
Restoration of miR-29a in PDAC cell lines downregulates target genes
To evaluate the effect of miR-29a on these five candidate targets, we performed western blot 
analysis in Panc-1 and MIA PaCa-2 cell lines transfected with control or miR-29a mimics at 
three different concentrations (5nM, 10nM and 20nM). For each 10nM and 20nM miR-29a 
dosage, expressions of all the five target proteins were significantly reduced in the two cell 
lines (Fig. 4B, Supplementary Fig. S3–A). However, for the 5nM dosage, the reduction in 
protein levels reached a significant threshold for the four genes except NRAS (Fig. 4B, 
Supplementary Fig. S3–A). This finding confirms a miR-29a mediated translational 
suppression mechanism in the five tested miR-29a targets.
Silencing the candidate targets reduces migration and EMT phenotypes in PDAC cells
GO analysis indicated the five identified targets to associate with cell migration 
mechanisms. Thus, to determine the effect of these candidates in PCC migration, we 
silenced the expression of the genes in Panc-1 and MIA PaCa-2 cells and seeded the cells for 
transwell assays. Knock-down of all the five targets significantly inhibited the migratory 
potential of the cells in MIA PaCa-2 cell line, with approximately 50% reduction in 
migration ability for LOXL2 (Supplementary Fig. S3–B). Significant reduction in migratory 
ability was observed in Panc-1 cells for four of the targets, except CLDN1 (Fig. 4C). 
Interestingly, in both Panc-1 and MIA PaCa-2 cell lines, among all five targets, silencing 
LOXL2 resulted in the highest inhibition of the migration of the cancer cells by around 50%, 
which mimics the migratory potential of miR-29a overexpressing cancer cells (Fig. 4C, 
Supplementary Fig. S3–B). Therefore, our data indicate that restoration of miR-29a or 
depletion of its downstream targets markedly impedes the migratory potential of PCCs.
Previously, we demonstrated that overexpressing miR-29a diminishes EMT phenotype in 
Panc-1 cell line (14). Here, we examined the effect of silencing the five miR-29a targets on 
EMT in the cell line (Fig. 4D). Western blot analysis showed that silencing each of the five 
targets resulted in increased expression of epithelial marker, E-cadherin, and decreased 
mesenchymal marker vimentin, with the most robust effects for siLOXL2 and siMYBL2. 
Together, these results suggest an association of miR-29a and its key targets with PDAC 
metastasis.
LOXL2 is a direct miR-29a target in PDAC cells
We next narrowed our focus on to LOXL2 as a primary candidate to perform additional 
functional analyses to elucidate miR-29a-LOXL2 axis in PDAC regulation. Firstly, LOXL2 
exhibited one of the highest fold changes among the downregulated targets in our primary 
candidate list from RNA-seq, and downregulation of the gene was most significantly 
correlated with survival in TCGA PDAC patients. Additionally, miR-29a gain-of-function 
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resulted in a robust depletion of LOXL2 protein expression, and loss of LOXL2 maximally 
impeded PCC migration and EMT. Given the unique tumor-stromal crosstalk associated with 
PDAC histopathology, LOXL2 appears to be the most relevant gene to study, being the only 
target that exhibits both intracellular and secreted functions in inducing EMT/metastatic 
phenotypes and regulating stromal remodeling via collagen crosslinking respectively 
(32,33).
To determine if LOXL2 is a direct miR-29a target in PCC lines, we identified the two 
putative miR-29a binding sites at the 3’-UTR of LOXL2 (positions 555–561 and 757–763) 
using TargetScan database. We then designed luciferase reporter assay with a vector 
encoding either WT LOXL2 miR-29a 3’-UTR binding site, or a sequence consisting of 
alternating point mutations within the miR-29a target binding region (Fig. 5A). Consistent 
with the predicted downregulatory role of miR-29a on LOXL2, we observed significantly 
reduced (~ 50%) luciferase activity for the Panc-1 and MIA PaCa-2 cells co-transfected with 
WT 3’-UTR carrying vector and miR-29a as compared to the non-specific control mimics, 
while co-transfection with the mutated 3’-UTR vector resulted in enhanced luminescence 
intensity abolishing the inhibitory effects of miR-29a (Fig. 5B, Supplementary Fig. S4–A). 
These data confirm that miR-29a directly binds to the 3’-UTR region of LOXL2 and 
negatively regulates the expression of the gene in PCC lines. Expectedly, silencing LOXL2 
had no effect on miR-29a expression in the two PCC cell lines (Supplementary Fig. S4–B). 
Next, to assess the MYC-miR-29a axis in regulation of LOXL2 expression, we first silenced 
MYC, which resulted in reduction of LOXL2 in Panc-1 and MIA PaCa-2 cell lines (Fig. 5C, 
Supplementary Fig. S4–C). Thereafter, we inhibited (i) miR-29a alone, or (ii) miR-29a and 
MYC simultaneously, both of which resulted in increased LOXL2 expressions (Fig. 5D). 
These observations suggest that LOXL2 expression is directly dependant on miR-29a in 
PCCs in MYC-silenced cells.
Gain of miR-29a function diminishes extracellular LOXL2 in PCCs
Because LOXL2 is a secreted protein and tumor-derived LOXL2 is known to influence 
tumor microenvironment, we next sought to study if miR-29a has an effect on extracellular 
LOXL2 function in PDAC. To this end, we analyzed the levels of secreted LOXL2 in CM 
obtained from Panc-1 and MIA PaCa-2 cells transfected with control or miR-29a mimics, 
and siCTRL or siLOXL2. Our results showed that in Panc-1 and MIA PaCa-2 cell lines, gain 
of miR-29a function resulted in 71% and 62% reduction in secreted LOXL2 levels 
respectively in the CM (Fig. 5E, Supplementary Fig. S4–D). To further validate whether 
ectopic miR-29a expression affected extracellular collagen crosslinking function of LOXL2, 
we estimated the newly crosslinked pepsin-soluble and heavily crosslinked insoluble 
collagen levels using Sircol and hydroxyproline assays respectively in the two PCC lines 
transfected with control or miR-29a mimics, and siCTRL or siLOXL2. Consistently, 
overexpressing miR-29a markedly depleted soluble and insoluble crosslinked collagen 
contents in the PCCs, similar to the effect observed for silencing LOXL2 (Fig. 5F&G, 
Supplementary Fig. S4–E&F). These results validate the regulatory role of miR-29a in 
extracellular collagen-crosslinking LOXL2 activity.
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Enhanced LOXL2 levels with reduced miR-29a expression observed in PanIN lesions/ 
PDAC in GEMM and clinical patient specimens
To assess the association between miR-29a and LOXL2 expression in PDAC in vivo and 
substantiate its clinical relevance, we first determined LOXL2 expression levels by 
immunohistochemistry analysis in pancreatic tissue samples from 4–6 months old mice 
belonging to a well characterized PDAC mouse model, KPC, that expresses the most 
common human oncogenic Kras (cancer-driver) and p53 (tumor-suppressor) mutations 
(KrasLSL.G12D/+; p53R172H/+; Pdx1-Cre), as well as in PDAC patient biopsies consisting of 
35–80% tumor stroma. In both KPC mice and clinical specimens, LOXL2 was highly 
expressed in pancreata with advanced PanIN or PDAC lesions, with little or no expression in 
normal regions or healthy tissues (Fig. 6A). Next, we evaluated the expression levels of 
LOXL2 and miR-29a in the pancreatic tissue samples from KPC mice via qPCR and 
compared that with age matched C57BL/6 control mice. In agreement with our in vitro 
observations, miR-29a expression in the KPC pancreatic tissue samples was significantly 
lower than the control C57BL/6 specimens with concomitant higher LOXL2 expression in 
KPC compared to C57BL/6 mouse tissues (Fig. 6B), confirming a negative correlation 
between miR-29a and LOXL2 in vivo. In our previous report, we demonstrated a significant 
reduction of miR-29a in PDAC patient tumors as compared to normal patient control 
pancreata (13). In TCGA PDAC patient data (n=178), although a small correlation was 
observed between miR-29a and LOXL2 by Pearson’s correlation test (R= −0.21), the inverse 
association was statistically significant (p= 3.9e−03), indicating a potential effect of the 
relationship in the context of PDAC patient prognosis (Fig. 6C). Together, these findings 
suggest that upregulation of LOXL2 is accompanied by concomitant suppression of miR-29a 
in PDAC in vivo, contributing to the disease progression.
Discussion
In the current study, we aimed to gain mechanistic insights into the upstream regulation of 
miR-29a, identify its global downstream effectors and discern their roles in PDAC 
pathogenesis. Here, we elucidate a novel miR-29a-mediated regulatory axis in PDAC 
pathogenesis. We have previously shown that in PCCs, pri-miR-29a/b1 and mature miR-29a 
expressions are commonly repressed compared to normal pancreatic epithelial cells (14) 
(Fig. 1A). Utilizing orthogonal loss-of-function approaches through siRNA mediated 
knockdown and small molecule inhibition, here we observed that miR-29a is repressed by 
MYC in PCCs. Because prior studies had indicated direct repressional regulation of several 
microRNAs including miR-29a by MYC in varied types of cells (15,26,34), we performed 
CHIP and luciferase assays to understand the regulation in PDAC. Our CHIP data 
demonstrated a direct binding of MYC at the miR-29a/b1 promoter binding site- a site 
where MYC was previously shown to repress miR-29a expression by recruiting EZH2 and 
causing H3K27 methylation mediated chromatin condensation (26,34). We further confirm a 
MYC-mediated repression of miR-29a at this binding site by luciferase assay. Thus, 
observations reported in the current study, in conjunction with prior evidence, suggest a 
direct MYC-mediated miR29a repression in pancreatic cancer.
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MYC is one of the central oncogenic TFs that is upregulated in approximately 40% of 
PDAC cases (35). MYC transcription is shown to be repressed by TGF-β/SMAD signaling, 
when TGF- β acts as a tumor-suppressor (36). Numerous studies have confirmed the context 
specific, paradoxical role of TGF-β in cancer (37–39). At early stages of tumorigenesis, 
TGF-β exhibits tumor-suppressive activities, while it “switches” to a pro-tumorigenic gene 
at a later stage in response to changes in the tumor microenvironment and mutations in Kras, 
which mediate inactivating mutations in tumor-suppressor genes CDKN2A, TP53 and 
SMAD4 (38–40). Notably, transition of PanIN to PDAC is characterized by the same 
activated Kras mutations (41). On the other hand, MYC is also a crucial downstream effector 
of Kras in the pancreatic cancer (42). Our previous findings demonstrate a pro-tumorigenic 
effect of TGF-β in pancreatic cancer, where we show that TGF-β1/SMAD4 signaling 
downregulates miR-29a expression in activated pancreatic stellate cells (PSCs) (13). In the 
same study we observed loss of miR-29a in Kras induced PDAC mice (13). Given that MYC 
is a downstream effector of both TGF-β and Kras signaling pathways- the pathways that also 
regulate miR-29a expression in PCCs, it is possible that the repression of miR-29a by MYC 
promoter binding is regulated by the Kras-TGF-β axis, or either by Kras or TGF-β signaling 
alone. However, it will be essential to design future studies to validate this supposition and 
further explore the upstream MYC-miR-29a regulatory axis in PDAC based on the current 
perspectives.
Our current RNA-seq offers one of the most comprehensive data on miR-29a regulated 
transcriptome in pancreatic cancer. We identified that the expression of 43 downstream 
miR-29a target genes, involved in ECM remodeling, cell migration, cellular growth and 
proliferation and/or metabolism, are reduced in PCC cells with restoration of miR-29a 
function. We found that in PCCs, miR-29a downregulates the expression of five prominent 
oncogenic targets (MYBL2, LOXL2, CLDN1, HGK and NRAS) both at transcriptional and 
translational levels. These five genes are particularly relevant in the context of PDAC 
because of their functional roles in mediating either or both ECM remodeling and cell 
migration/ metastasis- the classic mechanisms of PDAC progression, via diverse signaling 
pathways. For example, NRAS and HGK promote cell migration and proliferation via 
PI3K/Akt and JNK/ p38 pathways respectively (43,44). While CLDN1 is a tight junction 
protein known to promote cell migration/ invasion and EMT via Wnt/ β-catenin pathway 
(45), MYBL2 and LOXL2 promote both cancer cell proliferation and stromal desmoplasia 
via pathways such as Akt, NF-ĸβ, and Src/FAK (46–48). Here we show for the first time a 
miR-29a mediated regulatory axis of these genes in PDAC. Our findings suggest that loss of 
miR-29a in PCCs escalates tumor progression by de-repression of these pro-tumorigenic 
targets, perturbing the homeostasis of the cells. To assess the clinical relevance of the 
identified miR-29a-target regulatory axes, we compared the mRNA expressions of the genes 
with miR-29a from publicly available pancreatic adenocarcinoma patient datasets. The 
analysis revealed a negative correlation between the expressions of LOXL2, CLDN1, HGK 
and NRAS with miR-29a, largely supporting our data (Fig. 6C, Supplementary Fig. S5). 
Lack of a negative correlation between MYBL2 and miR-29a expressions perhaps reflects 
the heterogeneity in the biopsy specimens or its combination with other genetic factors 
associated with PDAC. Nonetheless, our findings advocate that restored expression of 
miR-29a in PDAC could offer a therapeutic advantage- the molecule being a single key 
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regulatory node to modulate multiple oncogenic targets associated with essential intra- and 
extracellular signaling pathways of tumor-stromal crosstalk, which are pivotal for the disease 
progression. Although the current work centers on further unraveling of the mechanisms of 
miR-29a-LOXL2 axis, future studies should be designed to functionally characterize each of 
the other four target genes of MYBL2, CLDN1, HGK and NRAS and their miR-29a 
mediated regulatory pathways in PDAC tumorigenesis.
Our data in this study show that in PCCs, miR-29a perturbs both intracellular and secreted 
LOXL2 function by repressing LOXL2 transcription via 3’-UTR binding. We observed 
increased levels of LOXL2 in both KPC mice and patient biopsy specimens, with inverse 
relationship with miR-29a (Fig. 6). Our in vitro study further indicates that loss of LOXL2 
in PCCs reduces the migration potential and EMT, which is consistent with other reports that 
demonstrate an intracellular, EMT promoting, LOXL2 function. Particularly, studies have 
shown that LOXL2 promotes EMT by direct downregulation of E-cadherin via interaction 
with Snail, a key TF in pancreatic cancer (49). Interestingly, we previously observed that 
overexpression of miR-29a results in an increase in E-cadherin in PCCs inducing 
mesenchymal-epithelial transition (MET) (14). However, E-cadherin is not a predicted 
miR-29a target (TargetScan), suggesting miR-29a to be an indirect player in E-cadherin 
regulation. This aligns with our current observations, and given our findings, it is reasonable 
to speculate that LOXL2 is likely the intermediate that bridges the gap between miR-29a and 
E-cadherin in regulation of EMT. Thus, our data support that in PCCs, repression of 
miR-29a de-represses LOXL2, which possibly promotes LOXL2-Snail interaction resulting 
in the downregulation of E-cadherin to escalate EMT phenotypes.
In our previous report, we have shown an anti-fibrotic function of miR-29a in pancreatic 
cancer tumor microenvironment, where miR-29a was found to inhibit major stromal protein 
expression and excessive stromal deposition by activated PSC (13). Here in this study, we 
evidence that restored expression of miR-29a in PCCs blocks LOXL2 secretion by the 
cancer cells potentially impeding the extracellular collagen crosslinking function of the 
protein. These observations are of great significance in the context of PDAC, where 
activated stroma is associated with poor patient prognosis and clinical outcome, and 
promotes aggressive, metastatic progression of the disease (4,50). Thus, it is apparent from 
our findings that the paracrine effect of miR-29a could encumber the transformation of 
quiescent PSCs to activated CAFs in the PDAC tumor microenvironment hindering 
metastasis-promoting stromal remodeling in the disease to facilitate efficient drug delivery 
to the tumor core.
Taken together, the current report provides novel insights into the regulatory mechanisms of 
miR-29a in inducing tumor-suppressive networks in PDAC, and advocates the importance of 
this molecule for therapeutic intervention. While our in vitro, in vivo and clinical 
observations elucidate the regulation and effects of the loss of miR-29a, and a MYC-
miR-29a-LOXL2 regulatory axis in PDAC, future studies using miR-29a knock-out mouse 
models will aid in further characterization of the regulatory role of the molecule in a 
physiological context, allowing to assess the prognostic and therapeutic appositeness of the 
molecule in targeting the disease.
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Figure 1: Knockdown/ inhibition of MYC results in increased miR-29a expression.
(A) qPCR analysis showing pri-miR-29a/b1 expression in normal human ductal epithelial 
cell lines (HPNE and HPDE) and human pancreatic cancer cell lines (Panc-1, MIA PaCa-2, 
BxPC-3, AsPC-1); n=4. (B) cBioportal analysis depicting the genetic alterations in the 
putative pri-miR-29a/b1 promoter binding transcription factors MYC, SMAD4, GLI3, NF- 
ĸB (NF- ĸB1) and YY1 in pancreatic adenocarcinoma patients from the TCGA database. 
(C) Regression plot indicating negative correlation between miR-29a expression (log2 
normalized+1) and MYC (z-score) in TCGA pancreatic adenocarcinoma patients with 
alterations in MYC. (D) Western blot analysis of Panc-1 cells transfected with siCTRL, 
siSMAD4, siMYC and siGLI3 and assessed for SMAD4, MYC and GLI3 with GAPDH as 
the loading control. (E) Mature miR-29a expression as observed by qPCR analysis for 
Panc-1 cells transfected with siCTRL, siSMAD4, siMYC and siGLI3; n=4. (F) qPCR 
analysis of total RNA from Panc-1 cells transfected with siCTRL and siMYC showing pri-
miR-29a/b1 expression; n=4. (G) Panc-1 cells were treated with various concentrations (1 
μM, 10 μM and 100 μM) of small molecule MYC inhibitor 10058-F4. Subsequently, total 
RNA was subjected to qPCR analysis for mature miR-29a expression levels; n=3. Numerical 
data are represented as average fold change (ΔΔCT) ± standard error of the mean (SEM); 
*p< 0.05, **p< 0.01.
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Figure 2: MYC nuclear localization negatively correlates with miR-29a and represses miR-29a 
by directly binding to the promoter region of the molecule in PDAC.
(A) Representative images for immunofluorescence (IF) staining of normal human ductal 
epithelial cell lines (HPNE and HPDE) and human pancreatic cancer cell lines (Panc-1, MIA 
PaCa-2, BxPC-3, AsPC-1) for MYC. Scale bar is 50 μm, 20X magnification. (B) Average 
percentage of nuclear co-localization plotted for relative pri-miR-29a/b1 expression for the 
cell lines presented as ± SEM; n=4. Co-localization was calculated based on DAPI nuclear 
staining and MYC IF. (C) Western blot analysis of MYC expression in nuclear and 
cytoplasmic fractions of HPNE, Panc-1, MIA PaCa-2, BxPC-3, AsPC-1 cell lines. 
Quantification of band intensities were normalized to LAMB1 for nuclear and GAPDH for 
cytosolic fractions respectively. (D) Schematic representation of the two MYC binding sites 
at the pri-miR-29a/b1 promoter region. (E) Luciferase reporter constructs containing 
miR-29a/b1 promoter region with MYC binding sites were co-transfected in Panc-1 cells 
with siCTRL or siMYC and renilla luciferase expression plasmid. All readouts were 
normalized to renilla luciferase activity and average relative luminescence normalized to 
respective controls is presented as ± SEM; n= 5, *p< 0.05. (F) Real-time PCR analysis of 
DNA fragments precipitated in a CHIP assay using Panc-1 cell line. Two primer pairs (C1 
and C2) designed within conserved MYC binding sites at miR-29a/b1 promoter and a primer 
pair for a validated MYC-binding region of CDKN1A were used to detect MYC- specific 
binding. Fold enrichment is represented as the signal obtained for MYC 
immunoprecipitation relative to that with IgG. Data presented as ± SEM; n= 3.
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Figure 3: RNA-seq analysis and identification of differentially expressed miR-29a target 
transcripts from the Panc-1 and MIA PaCa-2 datasets.
(A) Schematic representation of the RNA-seq analysis pipeline used to identify differentially 
expressed miR-29a target genes from the Panc-1 and MIA PaCa-2 datasets. (B) Volcano plot 
depicting the differentially expressed genes obtained from RNA-seq analysis for miR-29a 
overexpressing (OE) and control Panc-1 cells. (C) Correlation between differential 
expression (log2FC) of the transcripts identified by RNA-seq in the two different PDAC cell 
lines of Panc-1 and MIA PaCa-2. (D) Venn diagram of downregulated transcripts in Panc-1 
and/or MIA PaCa-2 datasets. Genes with logFC < 1, FDR<0.05 and p< 0.05 were only 
included. (E) The most enriched biological processes (GO terms) for the four ontologies 
(ECM Matrix Related, Metabolism, Migration/ Invasion or Cancer/Growth/Proliferation) 
associated with the overlapping miR-29a downregulated targets identified by RNA-seq are 
shown. The number on or outside each horizontal axis represents the gene number for a 
particular GO term. The false discovery rate value is shown as q-value for each GO. (F) 
Heatmap of the 43 overlapping downregulated miR-29a targets alongside the four associated 
GO categories.
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Figure 4: Functional validation of miR-29a downstream targets.
(A) Kaplan-Meier plots assessing the correlations between the seven miR-29a candidate 
gene (MYBL2, LOXL2, CLDN1, HGK, NRAS, FNDC5, and TUBD1) expressions and 
overall survival of TCGA pancreatic adenocarcinoma patients. (B) Panc-1 cells were 
transfected with different concentrations (5nM, 10nM and 20nM) of control (CTRL) or 
miR-29a mimics. Total protein was harvested from the cells 48 hrs post-transfection and 
subjected to western blot analysis for miR-29a candidate targets of MYBL2, LOXL2, 
CLDN1, HGK, and NRAS. GAPDH was used as the loading control. Quantification of band 
intensities normalized to GAPDH and relative to respective controls are represented as ± 
SEM; n=3, *p< 0.05, **p< 0.01, ***p< 0.001 (right). (C) Migration capacity of Panc-1 cells 
transfected with siCTRL, siMYBL2, siLOXL2, siCLDN1, siHGK, and siNRAS, or CTRL 
and miR-29a mimic were assessed by transmembrane cell migration assays. Relative cell 
migration was determined by the average number of migrated cells normalized to control 
(siCTRL and CTRL respectively) per 5 random fields and the data is presented as ± SEM; 
n=3, *p< 0.05, **p< 0.01, ***p< 0.001. (D) Total protein from Panc-1 cells transfected with 
siCTRL, siMYBL2, siLOXL2, siCLDN1, siHGK, and siNRAS, or CTRL and miR-29a 
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mimic were subjected to western blot analysis for E-cadherin and vimentin. GAPDH was 
used as the loading control.
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Figure 5: miR-29a directly downregulates LOXL2 in PDAC cell lines.
(A) Schematic representation of putative wild-type (WT) and mutated (Mut) binding sites of 
the miR-29 family members at the 3’-UTR region of LOXL2 used in luciferase assay. (B) 
Relative luciferase activity of LOXL2 3’-UTR WT and Mut reporter constructs co-
transfected with control (CTRL) or miR-29a mimics in Panc-1 cells. All readouts were 
normalized to renilla luciferase activity for each well, and average relative luminescence 
normalized to respective controls is presented as ± SEM; n= 6, **p< 0.01. (C) Western Blot 
for LOXL2 and MYC in Panc-1 cells transfected with siCTRL or siMYC. Relative protein 
levels were measured and normalized to GAPDH levels (indicated below). (D) Panc-1 and 
MIA PaCa-2 cells were transfected with LNA miRNA inhibitor control (siCT) or LNA 
miR-29a inhibitor (si-29a), and co-transfected with siCT and siCTRL (siCT1), or siMYC 
and si-29a. Total protein was subjected to western blot for LOXL2, and expression levels 
were normalized to GAPDH. (E) Panc-1 cells transfected with CTRL or miR-29a mimic, 
and siCTRL or siLOXL2 were cultured in serum free media for 48 hrs. Conditioned media 
thus obtained were subjected to ELISA for detection of secreted LOXL2. Data is presented 
as ± SEM; n= 4. ***p< 0.001. (F) Newly cross-linked pepsin-soluble collagen in ECM of 
Panc-1 cells transfected with CTRL or miR-29a mimic, and siCTRL and siLOXL2. Data is 
presented as ± SEM; n= 3. *p< 0.05; **p< 0.01 siCTRL (for siLOXL2). (G) 
Hydroxyproline content representing heavily cross-linked insoluble collagen in ECM of 
Panc-1 cells transfected with CTRL or miR-29a mimic, and siCTRL or siLOXL2. Data is 
presented as ± SEM; n= 3. *p< 0.05; **p< 0.01.
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Figure 6: Elevated LOXL2 levels inversely associate with miR-29a expression in KPC mice 
pancreas and human PDAC tumors.
(A) Upper panel: Representative photographs for immunohistochemical staining of LOXL2 
in pancreatic sections from control C57BL/6, and KrasLSL.G12D/+; p53R172H/+; Pdx1-Cre 
(KPC) mice at 4.5– 6 months of age (original magnification X20). While negative staining 
was observed for control C57BL/6, KPC mice pancreata with PanIN lesions (black arrows) 
and PDAC stained positive for LOXL2 with significantly higher LOXL2 expression. LOXL2 
positivity from immunohistochemistry analysis was quantified and presented as ± SEM; n= 
15 animals per group (right), ***p< 0.001. Lower panel: Representative photographs for 
immunohistochemical staining of LOXL2 in PDAC clinical specimens. Positive staining for 
LOXL2 was observed around PanIN (black arrows) and PDAC (red arrows) lesions in PDAC 
tumor specimens with little or no staining for normal patient pancreatic specimens. LOXL2 
positivity was quantified and presented as ± SEM (right); n= 6 for normal controls and n= 4 
for patient PDAC tumors, **p< 0.01. (B) Total RNA from frozen pancreatic tissue sections 
of C57BL/6 (n=7; solid blue) or KPC mice (n=8; solid purple) were isolated and subjected 
to qPCR analysis to determine miR-29a and LOXL2 expressions. miR-29a expression is 
represented by inverse triangles and LOXL2 expression is represented by triangles. Mean 
expressions of miR-29a and LOXL2 for each group are indicated as horizontal lines, **p< 
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0.01. (C) Correlation analysis between LOXL2 and miR-29a expressions in PDAC patients 
from the TCGA database (n= 178).
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Table 1:
miR-29a candidate targets identified from RNA-seq analysis in PDAC cells.





MYBL2/b-myb* MYB proto-oncogene like 2 −1.986 −2.869 0.287
LOXL2* Lysyl oxidase like 2 −2.053 −2.415 0.229
FNDC5 Fibronectin type III domain containing 
5
−2.159 −1.753 −0.212
CLDN1* Claudin 1 −1.246 −1.684 0.402
MAP4K4/ HGK* Mitogen-activated protein kinase kinase 
kinase kinase 4
−1.265 −1.494 0.302
NRAS* NRAS proto-oncogene, GTPase −1.428 −1.135 0.354
TUBD1 Tubulin delta 1 −1.199 −1.223 −0.253
*
indicates final candidate genes validated by functional assays in our study
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